Checkpoint Therapeutics Stock Price

-0.09 (-3.28%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Checkpoint Therapeutics Inc CKPT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.09 -3.28% 2.65 12:28:49
Open Price Low Price High Price Close Price Prev Close
2.72 2.64 2.75 2.74
Bid Price Ask Price Spread News
2.65 2.66 0.01 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,251 276,953 $ 2.69 $ 743,939 - 1.90 - 5.3762
Last Trade Time Type Quantity Stock Price Currency
12:28:49 3,000 $ 2.65 USD


Draw Mode:

Checkpoint Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 209.84M 79.18M 60.24M $ 1.07M $ - -0.41 -6.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 5.50%

more financials information »

Checkpoint Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CKPT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.702.972.642.83705,708-0.05-1.85%
1 Month3.083.2652.642.92933,026-0.43-13.96%
3 Months2.893.75992.222.901,578,284-0.24-8.3%
6 Months3.465.37622.223.191,427,459-0.81-23.41%
1 Year2.425.37621.903.121,171,9570.239.5%
3 Years2.835.37621.052.94522,865-0.18-6.36%
5 Years10.5010.501.052.97405,880-7.85-74.76%

Checkpoint Therapeutics Description

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.